THE SORIN BICARBON VALVE - CLINICAL-EVALUATION IN ISRAEL

Background Four collaborating centers pooled their results with the So rin Bicarbon Bileaflet valve. Material ann methods. Between 6/91 and 1 1/95, 431 patients, 235 males and 196 females, underwent valve replace ment using the new Sorin prosthesis; age range: 16-88, mean 61.4 yrs. Operations: AVR - 206, MVR - 177, TVR - 1, DVR - 47. Additional proced ures - 139: CAB - 117, valve repair - 22. AV sizes: 19-27, MV sizes: 2 1-33. Results. Thirty day mortality was 4.3%. Early complications incl uded: CVA - 1.4%, +ve blood culture -2%, reop for bleeding - 5%. Late complications: infective endocarditis - 2.3%, valve thrombosis - 0.2%, thromboemboli - 2.5%, major bleeding - 1.6%, reoperation - 3%, late d eaths (all causes) - 4.3%. No structural deterioration has been report ed with this valve and acceptable gradients have been observed. Hemoly sis is negligible. Conclusions. Based on this intermediate experience the Sorin Bicarbon prosthesis is well-designed with good hemodynamic p roperties, and an acceptably low incidence of complications.